Success Metrics

Active Trials

7(100%)

Phase Distribution

Ph early_phase_1

14%

Ph phase_3

14%

Ph phase_1

71%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Early Phase 1First-in-human

1(14.3%)

Phase 1Safety & dosage

5(71.4%)

Phase 3Large-scale testing

1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(7)

Detailed Status

Recruiting7

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (14.3%)

Phase 15 (71.4%)

Phase 31 (14.3%)

Trials by Status

recruiting7100%

Recent Activity

7 active trials

Showing 5 of 7

recruitingphase_1

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

NCT05850234

recruitingphase_1

A Study of AZD0120 in Autoimmune Diseases

NCT07295847

recruitingphase_3

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657

recruitingphase_1

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

NCT07073547

recruitingearly_phase_1

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

NCT07350837

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT05850234Phase 1

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Recruiting

NCT07295847Phase 1

A Study of AZD0120 in Autoimmune Diseases

Recruiting

NCT07391657Phase 3

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Recruiting

NCT07073547Phase 1

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Recruiting

NCT07350837Early Phase 1

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

Recruiting

NCT06897930Phase 1

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Recruiting

NCT07081646Phase 1

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Recruiting

All 7 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 7